Bladder cancer (BCa) exhibits molecular heterogeneity that complicates early diagnosis and prognosis, and drives confounding clinical outcomes. Non-muscle invasive and muscle-invasive subtypes, especially for intermediate to high grade, carry a 25%-50% progres... ...

请注册登录后继续浏览